Over-expression of metallothionein predicts chemoresistance in breast cancer

Journal of Pathology

Volumn 217, Issue 4, 2009, Pages 563-570

  Yap, Xinli ^a   Tan, Hong Yong ^b   Huang, Jingxiang ^a   Lai, Yiyang ^a   Yip, George Wai Cheong ^a   Tan, Puay Hoon ^b   Bay, Boon Huat ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Breast carcinoma; Chemosensitivity; Doxorubicin; Immunohistochemistry; Metallothionein

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METALLOTHIONEIN; METHOTREXATE; SMALL INTERFERING RNA; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ISOPROTEIN; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER GRADING; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CANCER TISSUE; CELL CYCLE; CELL NUCLEUS; CHEMOSENSITIVITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; CYTOTOXICITY; DOWN REGULATION; DRUG EXPOSURE; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MASTECTOMY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; BREAST TUMOR; CANCER STAGING; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; METALLOTHIONEIN; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL;

EID: 62849095868     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2489     Document Type: Article

References (37)

1. Kagi JHR, Vallee BL. Metallothionein: a cadmium- and zinccontaining protein from equine renal cortex. J Biol Chem 1960;235:3460-3465.
2. Kagi JHR, Vallee BL. Metallothionein: a cadmium- and zinccontaining protein from equine renal cortex. II. Physico-chemical properties. J Biol Chem 1961;236:2435-2442.
3. West AK, Stallings R, Hildebran CE, Chiu R, Karin M, Richards RI. Human metallothionein genes: structure of the functional locus at 16ql3. Genomics 1990;8:513-518.
4. Uchida Y, Takio K, Titani K, Ihara Y, Tomonaga M. The growth inhibitory factor that is deficient in the Alzheimer's disease brain is a 68 amino acid metallothionein-like protein. Neuron 1991;7:337-347.
5. Palmiter RD, Findley SD, Whitmore TE, Durnam DM. MT-III, a brain-specific member of the metallothionein family. Proc Natl Acad Sci USA 1992;89:6333-6337.
6. Quaife CJ, Findley SD, Erickson JC, Froelick GJ, Kelly EJ, Zambrowicz BP, et al. Induction of a new metallothionein isoform (MT-IV) occurs during differentiation of stratified epithelia. Biochemistry 1994;33:7250-7259.
7. Tai SK, Tan OJ, Chow VT, Jin R, Jones JL, Tan PH, et al. Differential expression of metallothionein 1 and 2 isoforms in breast cancer lines with different invasive potential: identification of a novel nonsilent metallothionein-1H mutant variant. Am J Pathol 2003;163:2009-2019.
8. Apostolova MD, Cherian MG. Nuclear localisation of metalloth ionein during cell proliferation and differentiation. Cell Mol Biol (Noisy-le-grand) 2000;46:347-356.
9. Nartey NO, Banerjee D, Cherian MG. Immunohistochemical localisation of metallothionein in cell nucleus and cytoplasm of foetal human liver and kidney, and its changes during development. Pathology 1987;19:233-238.
10. Sato M, Brenner I. Oxygen free radicals and metallothionein. Free Rad Biol Med 1993;14:325-327.
11. Cai L, Klein JB, Kang YJ. Metallothionein inhibits peroxynitriteinduced DNA and lipoprotein damage. J Biol Chem 2000;275:38957-38960.
12. Shimoda R, Achanzar WE, Qu W, Nagamine T, Takagi H, Mori M, et al. Metallothionein is a potential negative regulator of apoptosis. Toxicol Sci 2003;73:294-300.
13. Cherian MG, Howell SB, Imura N, Klaassen CD, Koropatnick J, Lazo JS, et al. Role of metallothionein in carcinogenesis. Toxicol Appl Pharmacol 1994;126:1-5.
14. Theocharis S, Margell A, Koutselinis A. Metallothionein: a multifunctional protein from toxicity to cancer. Int J Biol Markers 2003;18:162-169.
15. Bakka A, Endresen L, Johnson AB, Edminson PD, Rugstad HE. Resistance against cis-dichlorodiamminaplatinum in cultured cells with high content of metallothionein. Toxicol Appl Pharmacol 1981;61:215-226.
16. Satoh M, Cherian MG, Imura N, Shimizu H. Modulation of resistance to anti-cancer drugs by inhibition of metallothionein synthesis. Cancer Res 1994;54:5255-5257.
17. Sloane JP, Anderson TJ, Blarney RW, Brown CL, Chamberlain J, Coyne J, et al. Pathology reporting in breast cancer screening. In National Coordinating Group for Breast Cancer Screening Pathology, 2nd edn. Publication No 3. NHSBSP: Sheffield, 1995; 19-21.
18. Mididoddi S, McGuirt JP, Sens MA, Todd JH, Sens DA. Isoformspecific expression of metallothionein mRNA in the developing and adult human kidney. Toxicol Lett 1996;85:17-27.
19. Jin R, Bay BH, Chow VT, Tan PH, Dheen T. Significance of metallothionein expression in breast myoepithelial cells. Cell Tissue Res 2001;303:221-226.
20. Bier B, Douglas-Jones A, Totsch M, Dockhorn-Dworniczak B, Bocker W, Jasani B, et al. Immunohistochemical demonstration of metallothionein in normal breast tissue and benign and malignant breast lesions. Breast Cancer Res Treat 1994;30:213-221.
21. Fresno M, Wu W, Rodriguez JM, Nadji M. Localisation of metallothionein in breast carcinomas. An immunohistochemical study. Virchows Arch A Pathol Anat Histopath 1993;423:215-219.
22. Cherian MG, Jayasurya A, Bay BH. Metallothioneins in human tumours and potential roles in carcinogenesis. Mutat Res 2003;533:201-209.
23. Jin R, Bay BH, Chow VTK, Tan PH. Metallothionein IF mRNA correlates with histological grade in breast carcinoma. Breast Cancer Res Treat 2001;66:265-272.
24. Gallicchio LM, Flaws JA, Fowler BA, Ioffe OB. Metallothionein expression in invasive and in situ breast carcinomas. Cancer Detect Prev 2005;29:332-337.
25. Bay BH, Jin R, Huang J, Tan PH. Metallothionein as a prognostic biomarker in breast cancer. Exp Biol Med 2006;231:1516-1521.
26. Surowiak P, Matkowski R, Materna V, Gyorffy B, Wojnar A, Pudelko M, et al. Elevated metallothionein (MT) expression in invasive ductal breast cancers predicts tamoxifen resistance. Histol Histopathol 2005;20:1037-1044.
27. Petros WP, Hopkins PJ, Spruill S, Broadwater G, Vredenburgh JJ, Colvin OM, et al. Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J Clin Oncol 2005;23:6117-6125.
28. Kishi K, Doki Y, Miyata H, Yano M, Yasuda T, Monden M. Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer. Br J Surg 2002;89:597-603.
29. Wrigley E, Verspaget HW, Jayson GC, McGown AT. Metalloth ionein expression in epithelial ovarian cancer: effect of chemother apy and prognostic significance. J Cancer Res Clin Oncol 2000;126:717-721.
30. Siegsmund MJ, Marx C, Seemann O, Schummer B, Steidler A, Toktomambetova L, et al. Cisplatin-resistant bladder cell car cinoma: enhanced expression of metallothioneins. Urol Res 1999;27:157-163.
31. Volm M, Koomagi R, Mattern J, Efferth T. Protein expression profiles indicative for drug resistance of non-small cell lung cancer. Br J Cancer 2002;87:251-257.
32. Kondo Y, Kuo SM, Watkins SC, Lazo JS. Metallothionein local isation and cisplatin resistance in human hormone-independent prostatic tumour cell lines. Cancer Res 1995;55:474-477.
33. Davies KJ, Doroshow JH. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J Biol Chem 1986;261:3060-3067.
34. Doroshow JH, Davies KJ. Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide and hydroxyl radical. J Biol Chem 1986;261:3068-3074.
35. Quiles JL, Huertas JR, Battino M, Mataix J, Ramirez-Tortosa MC. Antioxidant nutrients and adriamycin toxicity. Toxicology 2002;180:79-95.
36. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999;57:727-741.
37. Rharass T, Vigo J, Salmon JM, Ribou AC. New method for the detection of reactive oxygen species in anti-tumoural activity of adriamycin: a comparison between hypoxic and normoxic cells. Free Radic Res 2008;42:124- 134.